In 2019, Merck KGaA, Darmstadt, Germany generated sales of €16.2 billion in 66 countries. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere.
Around 57,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry. and Canada, has some 22,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. You may later change your selection or discontinue this service.Ībout the Life Science business of Merck KGaA, Darmstadt, Germany or Canada please go to to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. More information on the company's contribution to the global Covid-19 response is available here: įollow MilliporeSigma on Twitter on Facebook and on LinkedIn.Īll Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. These expansions join MilliporeSigma's investments announced in 2020 to further enhance capabilities and capacity in Buchs, Switzerland Carlsbad, California Madison, Wisconsin and Darmstadt, Germany, broadening the company's global manufacturing footprint. This expansion is expected to bring nearly 275 roles by 2022, once the expansion is completed. The total investment in Jaffrey is about $22 million. These products are used to ensure the sterility of many lifesaving therapies and to remove viral contamination for a variety of therapies. The additional capacity includes new production lines and equipment to support the manufacturing of filtration devices and membrane products, specifically Durapore ® filters, Express ® filters, and the Viresolve ® product lines.
The Jaffrey expansion plans include adding 25,000 square feet to the existing 260,000-square-foot facility. The total investment in Danvers is about $25 million and will add approximately 400 jobs throughout 2021.
The expansion will add the capacity needed to support the manufacturing of products across several portfolios, including MilliporeSigma's Mobius ® single-use consumables. This expansion will add 65,000 square feet of space to the Danvers single-use assembly operations, adding to the existing 120,000-square-foot facility. "These investments will strengthen our global manufacturing footprint, allowing us to meet this unprecedented demand and help get lifesaving vaccines and therapies to more patients, faster." "The global coronavirus pandemic has significantly increased demand for our single-use and virus filtration technologies, which we are supplying to more than 50 different companies working on Covid-19 vaccine candidates," said Chris Ross, interim CEO, MilliporeSigma. MilliporeSigma's expansions, combined, are expected to create nearly 700 new jobs in New Hampshire and Massachusetts
0 kommentar(er)
